| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. | Prostate | 2010 | 1.14 |
| 2 | Calcitriol in cancer treatment: from the lab to the clinic. | Mol Cancer Ther | 2004 | 1.03 |
| 3 | ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. | Cancer Res | 2010 | 1.01 |
| 4 | Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. | Urol Oncol | 2006 | 0.93 |
| 5 | Calcitriol in the treatment of prostate cancer. | Anticancer Res | 2006 | 0.92 |
| 6 | Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. | Cancer Epidemiol Biomarkers Prev | 2004 | 0.80 |
| 7 | Effect of calcitriol on prostate-specific antigen in vitro and in humans. | Clin Cancer Res | 2006 | 0.79 |
| 8 | Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. | World J Urol | 2005 | 0.78 |